The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

about

The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study

P2860

Q47372771-073FA3C6-3387-427E-8A0E-E4F546003C30 Q57135067-6893BEE4-F6FC-480D-B556-DB3B61A06109

P2860

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

Item

http://www.wikidata.org/entity/Q38747402

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The 21-gene recurrence score i ...... ncer with favorable prognosis.

@en

type

Item

label

The 21-gene recurrence score i ...... ncer with favorable prognosis.

@en

prefLabel

The 21-gene recurrence score i ...... ncer with favorable prognosis.

@en

P1476

The 21-gene recurrence score i ...... ncer with favorable prognosis.

@en

P2093

Clifford Hudis

http://www.w3.org/2001/XMLSchema#string

Edi Brogi

http://www.w3.org/2001/XMLSchema#string

Gulisa Turashvili

http://www.w3.org/2001/XMLSchema#string

Hannah Y Wen

http://www.w3.org/2001/XMLSchema#string

Maura Dickler

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

P2888

s10549-017-4326-1

P304

65-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4326-1

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

Larry Norton

Monica Morrow

P577

2017-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085762262

http://www.w3.org/2001/XMLSchema#string

P698

28577081

http://www.w3.org/2001/XMLSchema#string

P932

5572649

http://www.w3.org/2001/XMLSchema#string

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

about

P2860

P2860

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932